Back to News
Market Impact: 0.25
Vaxcyte Set To Unveil Pivotal Phase 3 Data For Broad-Spectrum PCV Candidate; Today; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Vaxcyte (PCVX) is scheduled to present topline results from the pivotal Phase 3 OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, on October 5, 2026, via webcast and conference call. The article reports no trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
PCVX0.10
More News
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Vaxcyte shares surge on late-stage vaccine trial success
- Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more
- Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
- Stock Movers: Vaxcyte, Harley Davidson, CH Robinson (Podcast)
- Dow Gains 100 Points; ISM Services PMI Falls In September
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- Choosing an AI Copilot for Equity Research